Poseida Therapeutics (NASDAQ:PSTX) Rating Reiterated by HC Wainwright

Poseida Therapeutics (NASDAQ:PSTX)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued on Thursday, Benzinga reports. They presently have a $20.00 price target on the stock.

Poseida Therapeutics Stock Up 2.9 %

PSTX stock traded up $0.08 during mid-day trading on Thursday, reaching $2.87. 549,987 shares of the company traded hands, compared to its average volume of 696,517. The stock has a market cap of $278.19 million, a price-to-earnings ratio of -2.06 and a beta of 0.46. The company has a quick ratio of 3.18, a current ratio of 3.18 and a debt-to-equity ratio of 0.56. Poseida Therapeutics has a fifty-two week low of $1.54 and a fifty-two week high of $4.27. The firm’s 50 day moving average price is $2.96 and its 200 day moving average price is $2.94.

Poseida Therapeutics (NASDAQ:PSTX) last released its quarterly earnings results on Thursday, March 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.09. The business had revenue of $25.00 million during the quarter, compared to the consensus estimate of $12.50 million. Poseida Therapeutics had a negative return on equity of 94.90% and a negative net margin of 190.76%. As a group, equities research analysts predict that Poseida Therapeutics will post -1.77 EPS for the current fiscal year.

Hedge Funds Weigh In On Poseida Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Public Employees Retirement System of Ohio purchased a new position in shares of Poseida Therapeutics in the 4th quarter worth approximately $76,000. Cantor Fitzgerald L. P. purchased a new position in shares of Poseida Therapeutics in the 4th quarter worth approximately $169,000. Tower Research Capital LLC TRC boosted its stake in shares of Poseida Therapeutics by 110.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,679 shares of the company’s stock worth $36,000 after buying an additional 5,606 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in shares of Poseida Therapeutics in the 4th quarter worth approximately $36,000. Finally, MCF Advisors LLC boosted its stake in shares of Poseida Therapeutics by 476.4% in the 4th quarter. MCF Advisors LLC now owns 247,024 shares of the company’s stock worth $830,000 after buying an additional 204,170 shares during the last quarter. Institutional investors and hedge funds own 46.87% of the company’s stock.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.